Smart dosing strategy could keep rheumatoid arthritis under control

NCT ID NCT06440629

Ongoing Disease control Sponsor: Diakonhjemmet Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This study compares two ways of managing rheumatoid arthritis in people taking adalimumab. One group gets standard care, while the other has their dose adjusted based on regular blood tests that measure drug levels and antibodies. The goal is to see if personalized dosing helps maintain disease control without flares over 18 months. About 350 adults with stable, low disease activity will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: adalimumab (a tumor necrosis factor inhibitor)
What this could lead to: If successful, this approach could help people with rheumatoid arthritis maintain disease control with fewer flares by personalizing their medication dose.
What could go wrong: This is a Phase 4 study, so the drug is already approved. The main uncertainty is whether routine dose adjustments will actually reduce flares more than standard care, and some patients may need to switch therapies if antibodies develop.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Locations

Betanien Hospital

Skien, 3722, Norway
Carol Davila University of Medicine and Pharmacy Bucharest

Bucharest, Romania
Diakonhjemmet sykehus

Oslo, N-0319, 0319, Norway
Drammen Hospital

Drammen, 3004, Norway
Førde Hospital Trust

Førde, 6812, Norway
Haugesund Rheumatism Hospital

Haugesund, 5528, Norway
Haukeland University Hospital

Bergen, 5009, Norway
Helgeland Hospital Trust

Mo i Rana, 8613, Norway
Hospital of Southern Norway Trust

Kristiansand, 4615, Norway
Humanitas Research Hospital

Milan, Italy
Karolinska University Hospital

Stockholm, 141 86, Sweden
Lillehammer Hospital for Rheumatic Diseases

Lillehammer, 2609, Norway
Martina Hansen's Hospital

Sandvika, Norway
Medical University Vienna

Vienna, A-1090, Austria
Nordland Hospital Trust

Bodø, 8005, Norway
Queen Mary

London, SW15 5PN, SW15 5PN, United Kingdom
Sahlgrenska Universitetssjukehuset

Gothenburg, 41345, Sweden
St.Olavs Hospital

Trondheim, 7030, Norway
Stavanger University Hospital

Stavanger, 4019, Norway
University Hospital of North Norway

Tromsø, 9019, Norway
Ålesund Hospital

Ålesund, 6017, Norway
Østfold Hospital Trust

Moss, 1535, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.